SES - Delayed Quote SGD

China Medical System Holdings Limited (8A8.SI)

1.5900 0.0000 (0.00%)

At close: November 2 at 11:51:26 AM GMT+8

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

GlobeNewswire 1mo ago

0867.HK

8A8.SI
0.00%
CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

GlobeNewswire 1mo ago

0867.HK

8A8.SI
0.00%
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

GlobeNewswire 4mo ago

0867.HK

8A8.SI
0.00%
CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

GlobeNewswire 4mo ago

0867.HK

8A8.SI
0.00%
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

GlobeNewswire 6mo ago

0867.HK

8A8.SI
0.00%
CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

GlobeNewswire 6mo ago

8A8.SI
0.00%
0867.HK
Leios Therapeutics Announces Exclusive Licensing Agreement and Strategic Investment with Subsidiaries of China Medical System Holdings Ltd. for 10XB-101

GlobeNewswire 2mo ago

0867.HK
Beyang Closes Oversubscribed $30 Million Series A Financing

PR Newswire 2mo ago

0867.HK
Beyang Closes Oversubscribed $30 Million Series A Financing

PR Newswire 2mo ago

0867.HK
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

GlobeNewswire 8mo ago

CHSYF
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

GlobeNewswire 10mo ago

CHSYF

U.S. markets open in 4h 31m

China Medical System Holdings Limited (8A8.SI)

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

Leios Therapeutics Announces Exclusive Licensing Agreement and Strategic Investment with Subsidiaries of China Medical System Holdings Ltd. for 10XB-101

Beyang Closes Oversubscribed $30 Million Series A Financing

Beyang Closes Oversubscribed $30 Million Series A Financing

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China